Menu
Start Screening

Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

Treatment of Major Depression Medicine The British Journal of Psychiatry

3 papers

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial

Colleen Loo, Nick Glozier, Dávid Barton, Bernhard T. Baune, Natalie Mills, Paul B. Fitzgerald, et al.
The British Journal of Psychiatry Summary & key facts 2023 60 citations

Researchers tested repeated subcutaneous (under-the-skin) injections of racemic ketamine in people whose depression had not improved after at least two antidepressant trials. People got injections twice a week for 4 weeks and neither participants nor the raters knew which drug they were getting. When the study allowed higher, response-guided ketamine…

Mental Health Research Topics Treatment of Major Depression Tryptophan and brain disorders Ketamine

Examining the needs, outcomes and current treatment pathways of 2461 people with treatment-resistant depression: mixed-methods study

Kiranpreet Gill, Danielle Hett, Max Carlish, Rebekah Amos, Ali Khatibi, Isabel Morales-Muñoz, et al.
Cambridge Core Summary & key facts 2026 5 citations

This mixed-methods study used NHS electronic health records and interviews to look at people with major depressive disorder in one large UK trust. Using a common definition of treatment-resistant depression (failure to respond to at least two antidepressant trials), the researchers found TRD was common (48% of the sample) and…

Cardiac Health and Mental Health Mental Health Treatment and Access Treatment of Major Depression

Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study

Natalie T Mills, Stevan Nikolin, Nick Glozier, David Barton, Bernhard T Baune, Paul B Fitzgerald, et al.
Cambridge Core Summary & key facts 2025 1 citation

In a randomized, double-blind trial, people with treatment-resistant depression received subcutaneous ketamine twice a week for 4 weeks. When doses were flexible and could be increased (0.5–0.9 mg/kg), anxiety scores fell more with ketamine than with the active control; this was not seen with a fixed low dose (0.5 mg/kg).…

Functional Brain Connectivity Studies Treatment of Major Depression Tryptophan and brain disorders
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.